METHOD FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC HEPATITIS B, CHRONIC HEPATITIS C AND AUTOIMMUNE LIVER DISEASES IN PATIENTS WITH SEVERE FIBROSIS AND CIRRHOSIS Russian patent published in 2025 - IPC G01N33/68 G01N33/573 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to hepatology, laboratory diagnostics, and can be used for differential diagnosis of chronic hepatitis B (CHB), chronic hepatitis C (CHC) and autoimmune liver diseases (AILD) in patients with severe fibrosis and cirrhosis. Blood plasma is analysed for concentration of IL-18 cytokines in pg/ml, TNFα in pg/ml, IFN2α in pg/ml. Diagnosis in a patient with severe fibrosis and cirrhosis is established by comparing the obtained values with threshold values: at the first stage, IL-18 concentration is assessed, if the value is less than 32.43 pg/ml, AILD is diagnosed, the value of more than or equal to 32.43 pg/ml requires the second stage. At the second stage, the concentration of IFN2α is assessed, if the value is less than 47.15 pg/ml, CHB is diagnosed, while the value is more than or equal to 47.15 requires the third stage. At the third stage, TNFα concentration is assessed, if the value is less than 41.32 pg/ml, AILD is diagnosed, if the value is more than or equal to 41.32, CHC is diagnosed.

EFFECT: method enables differential diagnosis of chronic hepatitis B, chronic hepatitis C and autoimmune liver diseases, including autoimmune hepatitis and primary biliary cirrhosis, in patients with severe fibrosis and cirrhosis (F3-4) with a high level of sensitivity and maintaining the required specificity by determining three cytokines in blood plasma: IFN2α, TNFα and IL-18.

1 cl, 1 dwg, 3 ex